Microalbuminuria (urinary albumin excretion equal to 30-300 mg/24 h) is a reliable indicator of premature cardiovascular mortality in diabetic patients and in the general population. In insulin-dependent and non-insulin-dependent diabetes mellitus microalbuminuria is a marker of initial diabetic nephropathy and predicts the evolution toward renal insufficiency. In essential hypertension the clinical and prognostic role of microalbuminuria is more controversial. While it is a recognised marker of cardiovascular complications and a reliable predictor of ischaemic heart disease, its prognostic value on the risk of progressive renal alterations is still uncertain because no prospective studies, taking microalbuminuria as a selection criterion and renal insufficiency as an end point, are available. Blood pressure control with antihypertensive drugs is accompanied by a reduction in urinary albumin excretion. The favourable effects of antihypertensive agents on microalbuminuria appear to be proportional
Introduction
Microalbuminuria (urinary albumin excretion (UAE) of 20-200 g/min, corresponding to 30-300 mg/24 h) has been regarded as an important prognostic indicator since, in various clinical conditions, has shown to be related with higher cardiovascular risk and progressive renal damage.
In insulin-dependent and non-insulin-dependent diabetes mellitus microalbuminuria is also a reliable marker of initial diabetic nephropathy, predicts the appearance of overt proteinuria and the evolution toward chronic renal failure. [1] [2] [3] In maturity onset diabetes and in elderly subjects, microalbuminuria predicts premature cardiovascular mortality 3, 4 and in men of the general population aged Ͼ40 years is an independent risk factor for coronary artery disease. 5 In essential hypertension, microalbuminuria is a recognised marker of cardiovascular complications and a reliable predictor of ischaemic heart disease. 6 Conversely, the prognostic value of increased UAE Correspondence: G Crippa, MD, Hypertension Unit, Civil Hosptial, Via Taverna 49, 29100 Piacenza, Italy E-mail: crippagȰaltrimedia.it to blood pressure reduction, but angiotensin-converting enzyme inhibitors and angiotensin-II-receptor antagonists show an additional beneficial effect on urinary albumin excretion. Whether the reduction of microalbuminuria obtained through pharmacological intervention has favourable prognostic implications remain to be demonstrated. However, screening for microalbuminuria is a relatively easy and inexpensive procedure and reveals a potentially treatable abnormality. Thus, considering that microalbuminuria identifies hypertensive subjects at higher risk than standard, urinary albumin excretion should be routinely measured in hypertensive patients and, in the presence of microalbuminuria, antihypertensive treatment should be intensified in order to obtain an optimal blood pressure control. microalbuminuria as a predictor of impaired renal function remains controversial among hypertensive subjects because no prospective studies taking microalbuminuria as a selection criterion and renal insufficiency as an end point are available.
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Significance of microalbuminuria
Experimental and clinical studies recognise two major causes for the increased UAE in essential hypertension:
• haemodynamic changes leading to elevation in intraglomerular pressure; • generalised angiopathy, perhaps related to endothelial dysfunction, characterised by renal and systemic transvascular albumin leakage.
Among hypertensive patients the prevalence of microalbuminuria is about 25% and is higher than that observed in diabetic patients (20%).
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Microalbuminuria and cardiovascular risk
Microalbuminuria is related to a number of clinical variables such as age, gender, race, hyperglycaemia, hyperlipaemia, hyperinsulinaemia, hypertension, obesity, left ventricular hypertrophy, smoking habits, diet etc. Practically, all recognised cardiovascular risk factors are related to microalbuminuria. However, they do not account for the whole variance in UAE 8 as if other and still unknown determinants could be more important in the pathogenesis of microalbuminuria and its relationship with cardiovascular diseases.
Microalbuminuria has a definitely higher prevalence in hypertensive subjects than in the general population 7, 9 and there is convincing evidence of independent relationships between its presence and diastolic blood pressure levels, 10 pulse pressure, and isolated systolic hypertension.
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These relationships become even closer when blood pressure levels are evaluated through ambulatory blood pressure monitoring [12] [13] [14] which provides a more precise estimation of the real blood pressure status.
Microalbuminuria (as well as the other major cardiovascular risk factors) could simply reflect an augmented susceptibility to atherosclerosis linked to common pathogenetic factors (for instance endothelial dysfunction).
The relationship between microalbuminuria and atherosclerotic processes seems very tight and increased UAE has been considered a marker of prevalent subclinical atherosclerosis. [15] [16] [17] Clinical studies have clearly shown that among hypertensive patients with microalbuminuria an increased cardiovascular risk exists compared to normoalbuminuric patients with similar blood pressure levels. 10 This correlation is particularly evident for coronary artery disease: it has been pointed out that microalbuminuria is the strongest independent determinant of ischaemic heart disease since confers a four-fold increased risk for this illness among hypertensive or borderline hypertensive subjects. 6 
Microalbuminuria and renal disease
Among hypertensive patients the relationship between increased UAE and impaired renal function is still uncertain.
Microalbuminuria might be an expression of renal damage induced by hypertension but also the sign of a generalised vascular alteration. 18 The role of microalbuminuria as a prognostic indicator of future renal damage has only been demonstrated in diabetics 1 while in essential hypertension no such data are available yet.
What is certain, in essential hypertension, is that microalbuminuria is associated with other conditions characterised by high risk profile and poorer renal prognosis. In fact, increased UAE is more prevalent in salt-sensitive, high-renin, obese and African-American hypertensives, [19] [20] [21] conditions that are known to be related with a higher prevalence of renal insufficiency than the rest of the hypertensive population. Furthermore, essential
Journal of Human Hypertension hypertensive subjects with enhanced UAE show a loss of nocturnal blood pressure decline (nondipping pattern) 22 as it happens in more severe degrees of essential hypertension and in patients with hypertension due to renal disease. Whether microalbuminuria indicates an underlying renal disease or an early renal damage due to hypertension remains to be elucidated.
Thus, if there are no unequivocal evidence that microalbuminuria is a marker for developing renal insufficiency there are at least strong hints that support this conclusion. Increased UAE seems to identify a subgroup of hypertensive patients at higher risk of developing renal (and cardiovascular) complication. It has been found that macroalbuminuria (UAE Ͼ300 mg/24 h, detectable with reactive strips) is related with a progressive decline in renal function 17 and it is difficult to postulate that renal disease with overt proteinuria does not pass through a microalbuminuric stage. Assessing the prognostic value of microalbuminuria in monitoring the progression of hypertensive renal alteration is very difficult since end-stage renal disease takes a long time to become established. 23 However, considering that either glomerular filtration rate decline or proteinuria are not sensitive end points in the mildest forms of renal disease (such as the one related to essential hypertension) it emerges that microalbuminuria can be considered the best surrogate end point to evaluate hypertensive patients at risk of developing renal failure.
Antihypertensive drugs and microalbuminuria
Blood pressure control with antihypertensive medications is accompanied by a reduction (but not a normalisation) in UAE. Redon has performed a comprehensive review of the most recent studies (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) to assess whether antihypertensive agents differ with respect to their action on microalbuminuria. 24 Although some data are discordant, all of these studies showed that reduction of blood pressure with ACE-inhibitors, some calcium channel blockers, beta-blockers, diuretics, alpha-1-blockers and angiotensin-II receptor antagonists also reduce UAE. Furthermore, the majority of the studies report better outcomes for ACE-inhibitors when compared with other drugs, except for the angiotensin-II receptor antagonist losartan, which results at least as effective as enalapril.
The favourable effects of antihypertensive agents on microalbuminuria appear to be proportional to blood pressure reduction, but angiotensin-converting enzyme (ACE)-inhibitors and angiotensin-II receptor antagonists show an additional beneficial effect on UAE which is independent of blood pressure reduction.
In different studies and models, treatment with nifedipine has shown controversial effects on uri- nary protein excretion with some data indicating a decrease, and others an increase in albuminuria. [25] [26] [27] [28] These conflicting results could be due to the different actions of the short-acting and the long-acting (GITS) formulation of this drug. In a first investigative series we evaluated the effect of short-acting nifedipine and captopril fixed doses on UAE. 29 Thirty-two patients with untreated mild-to-moderate essential hypertension and microalbuminuria, after a 4-week period of low-sodium fixed-protein diet, were randomly treated with nifedipine (10 mg thrice daily) or captopril (25 mg thrice daily). UAE (average of two 24-h collections) at baseline was compared with that observed after 12 weeks of pharmacological treatment. The same protocol was later carried out in a group of other 32 mild-to-moderate hypertensives to investigate the effect of long-acting (GITS) nifedipine 30 mg vs enalapril 20 mg. 30 The results of the two studies are summarised in Table 1 . As expected, both ACE-inhibitors reduced UAE at the same extent. The two different formulations of nifedipine showed opposite effects on microalbuminuria: short-acting nifedipine significantly increased while nifedipine GITS significantly decreased UAE, despite very similar effects on blood pressure.
These data indicate that the particular pharmacodynamics and pharmacokinetics of short-acting nifedipine (characterised by rapid absorption, abrupt onset and short duration of action), determining quick vasodilatation and reflex vasoconstriction due to neurohumoral activation, may play an important role in this apparent discrepancy on UAE.
In fact the rapid fluctuation of systemic blood pressure, caused by short-acting nifedipine, could 'catch' the preglomerular and afferent arteriole still dilated when systemic blood pressure is increasing due to sympathetic and hormonal activation, allowing a greater transmission of systemic blood pressure to the glomerular capillaries and thus augmenting albuminuria.
Whether the reduction of UAE determined by different pharmacological interventions has favourable prognostic implications remains to be demonstrated through ad hoc designed studies.
In hypertensive patients, screening for microalbuminuria is a relatively easy and inexpensive procedure and reveals a potentially treatable abnormality.
Thus, in the presence of increased UAE, independently from its intrinsic significance (renal damage secondary to hypertension or underlying renal and systemic endothelial dysfunction) antihypertensive treatment should be intensified and blood pressure control optimised, since microalbuminuria identifies hypertensive subjects at higher risk than standard.
